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5-Bromo-2-deoxyuridine activates DNA damage signalling
responses and induces a senescence-like phenotype in
p16-null lung cancer cells
Joanne C. Masterson and Shirley O’Dea
5-Bromo-2-deoxyuridine (BrdU) is a thymidine analogue
that is incorporated into replicating DNA. Although
originally designed as a chemotherapeutic agent, sublethal
concentrations of BrdU have long been known to alter the
growth and phenotype of a wide range of cell types.
Mechanisms underlying these BrdU-mediated effects
remain unknown, however. We have characterized the
effects of BrdU on A549 lung cancer cells by examining
DNA damage responses, cell cycle effects and phenotypic
changes. A549 cells express wild-type p53, but are p16-
null. Sublethal concentrations of BrdU evoke a DNA
damage response in these cells that involves the activation
of Chk1, Chk2 and p53. Increased numbers of enlarged
nuclei and multinucleated cells are evident in the treated
populations. Cell cycle inhibition occurs, resulting in
reduced proliferation and accumulation of cells in the S,
G2/M and G0 phases. BrdU induces an early inhibition of
p21 expression that coincides with nuclear localization of
proliferating cell nuclear antigen. Subsequently, p21 levels
increase, whereas proliferating cell nuclear antigen levels
decrease compared with control cells. Upregulation of p27
and p57 expression also occurs. By day 7 of exposure to
BrdU, treated cells acquire a senescent-like phenotype
with an increase in cell size, granularity and b-
galactosidase activity. We conclude that BrdU induces a
DNA damage response in A549 cells, which results in
reduced proliferation mitotic exit and phenotypic changes
that resemble senescence. Anti-Cancer Drugs
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Introduction
Although currently widely used to measure DNA synth-
esis in proliferating cells, the halogenated pyrimidine, 5-
bromo-2-deoxyuridine (BrdU), was originally rationally
designed in the 1950s as a thymidine analogue to perturb
DNA synthesis in cancer cells. BrdU was subsequently
found to be a potent radiosensitizer and photosensitizer
[1–3], and trials using combined chemotherapies that
include BrdU as a radiosensitizer continue today [4].
BrdU incorporation into DNA results in several types of
DNA lesions, including mutations [5], fragile sites [6],
chromatid breaks [7] and sister chromatid exchanges [8].
In addition, BrdU induces micronucleation [9], hyper-
methylation of DNA [10] and polyploidization [11].
Remarkably, investigations into the DNA damage re-
sponses elicited by BrdU incorporation into cellular DNA
are limited. The mismatch-repair system is activated in
BrdU-containing cells [12,13]. Other than this, little is
known regarding the damage pathways that are activated
by BrdU, and their consequences for cell cycle and cell
fate.
In addition to its DNA-damaging effects, early studies
with BrdU revealed significant effects on cell morphology
and phenotype in various cell types [14]. Subsequently,
BrdU became known as a differentiating agent owing to
its effects on the morphology and phenotype of a wide
range of cell types in vitro and in vivo, including normal
chondrocytes, muscle, molar, brain, pancreatic and blood
cells [15–20], and leukaemic and lung cancer cells
[21–24]. More recently, the Ayusawa group [25,26] has
reported that BrdU induces a senescent-like phenotype
in both normal and transformed cells. Senescence,
particularly in transformed cells, remains relatively poorly
defined; it is now unclear whether the phenotypic
changes observed in BrdU-treated cells in earlier studies
were, in fact, senescence-related events rather than true
differentiation effects. The Ayusawa group in their
reports did not address this question. The ability of a
chemotherapeutic agent, such as BrdU, to induce
differentiation or senescence is potentially a desirable
side effect that can enhance its antitumour activity.
Moreover, BrdU might have clinical potential as a
differentiation therapeutic, distinct from its chemother-
apeutic role. Conversely, it remains to be proved whether
the induction of senescence in tumours is, in fact,
advantageous. Evidence exists that senescent cells can
alter the microenvironment surrounding preneoplastic
0959-4973 c 2007 Lippincott Williams & Wilkins
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
cells and may encourage tumour growth [27]. The
cellular effects and the mechanisms of action of BrdU,
therefore, require clarification in this context.
Suggested mechanisms underlying the effects of BrdU
on gene expression and cell phenotype include DNA
mutations, alterations in DNA methylation, altered
interactions with DNA-binding proteins and reversal of
the remodelling of regulatory DNA into specific chroma-
tin architecture that occurs during cancer. BrdU-sub-
stituted DNA has an increased capacity to bind histones
[28], nonhistone proteins [29] and chromosomal proteins
[30], and might become concentrated in repetitive DNA
nucleotide sequences [31]; such observations have,
however, not yet been linked to downstream effects.
The Ayusawa group speculates that BrdU incorporation
into AT-rich inactive chromatins, such as in scaffold/
nuclear matrix attachment region (S/MAR) sequences,
results in altered interactions with AT-binding ligands
and leads to changes in gene expression consistent with
senescence [32,33]. The mechanisms underlying the
subsequent halting of the cell cycle and the induction of a
senescence-like phenotype, however, remain unexamined
and unexplained.
In this study, we have characterized the DNA damage
response and cell cycle effects of BrdU in A549 lung
cancer cells. The A549 cell line is widely used for lung
studies. These adenocarcinoma-derived cells contain
wild-type p53 and pRb but do not express p16, a protein
usually required for senescence [34]. The cell line is also
aneuploid and contains chromosomal abnormalities [35],
and heterogenous subpopulations [36]. We report that
the DNA damage response to BrdU in these cells involves
the activation of Chk1, Chk2 and p53. Subsequent cell
cycle effects include halts at G0, S and G2/M phases, and
morphological changes consistent with the induction of a
senescent-like phenotype. It has recently been proposed
that the induction and maintenance of senescence
requires the efficient activation of the DNA damage
response pathways [37,38]. Our data are consistent with
this and indicate that DNA damage responses in BrdU-
treated cancer cells lead to the inhibition of cell cycles
and to the establishment of a senescence-like phenotype.
Materials and methods
Cell culture and 5-bromo-2-deoxyuridine treatment
The A549 lung adenocarcinoma cell line was obtained
from the European Collection of Cell Cultures (Salisbury,
UK). Cells were routinely cultured in a 1 : 1 mixture of
Dulbecco’s modified Eagle’s medium and Hams F12
(Gibco, Paisley, UK), supplemented with 5% fetal bovine
serum (Gibco) and 2mmol/l of L-glutamine (Gibco).
Cells were maintained in a humidified atmosphere
containing 5% CO2 and 95% air at 371C. Stock solutions
of 10mmol/l of BrdU (Sigma, Poole, UK) were prepared
in sterile water and stored at – 201C. Cells were seeded
at 0.3 103/cm2 in tissue-culture vessels, appropriate to
each assay. After 24 h BrdU was added at a final
concentration of 10 mmol/l in a volume of 200 ml/cm2
(day 0). The medium was replaced with fresh BrdU-
containing medium on day 3 and cells were harvested for
assays as appropriate.
Cell proliferation
Cells were seeded into 24-well plates and BrdU was
added after 24 h. At each time point, both suspension
cells and adherent cells were harvested. Adherent cells
were harvested by trypsinization. Viability counts were
carried out using ethidium bromide/acridine orange
staining and an ultraviolet microscope. Total cell counts
were obtained by combining the suspension and adherent
cell counts.
Immunofluorescence
Cells were seeded into eight-well chamber slides (Nalge
Nunc, Naperville, Illinois, USA) and BrdU was added
after 24 h. At appropriate time points, cells were fixed in
ice-cold methanol for 5min and blocked in 20% serum.
Cells were then incubated with antiphosphorylated Chk1
(Ser 345), antiphosphorylated Chk2 (Thr68), anti-p53,
antiphosphorylated-p53 (Ser 15, 37 or 46), antiphos-
phorylated Rb (Ser 807/811) (Cell Signaling, New
England Biolabs, Hitchin, UK), antiproliferating cell
nuclear antigen (PCNA), anti-p27 (Sigma), anticyclin
D1, anti-p57, anti-p21 (Santa Cruz Biotechnology,
Heidelberg, Germany) or anti-actin (Sigma). Alexa 488
secondary antibodies (Molecular Probes, Invitrogen,
Paisley, UK) were used for visualization. Nuclei were
counterstained with DAPi (Sigma). Slides were mounted
in fluorescent aqueous mounting media (Dako Cytoma-
tion, Galway, Ireland) and photomicrographs were
acquired using a fluorescent microscope or confocal
microscope, as indicated.
Fluorescence flow cytometry
Cells were seeded into 75-cm2 tissue-culture flasks and
BrdU was added after 24 h. On day 7 of treatment, cells
were harvested by trypsinization and washed twice in
phosphate-buffered saline (PBS) before being fixed in
70% ice-cold ethanol. Cells were washed twice in PBS/1%
fetal bovine serum to remove ethanol and blocked with
neat rabbit serum. For detection of p21, cells were
incubated with anti-p21 antibody (Santa Cruz Biotech-
nology) followed by a secondary rabbit antimouse anti-
body conjugated to Alexa 488 fluorescent dye (Molecular
Probes). For detection of cyclin B1, Ki-67 (BD Bio-
sciences, Oxford, UK) and pan-keratin (Sigma), cells
were incubated with primary antibodies conjugated to
fluorescein isothiocyanate fluorescent dye. Fluorescence
was detected using a FACScan flow cytometer (Becton
Dickenson, BD Biosciences) and analysed using Cell-
Quest software (Becton Dickenson, BD Biosciences).
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Western blot analysis
Cells were lysed in radioimmunoprecipitation (RIPA)
buffer for total protein extracts. Ten micrograms of
protein was separated by sodium dodecyl sulphate–
polyacrylamide gel electrophoresis and transferred onto
a nitrocellulose membrane. Blots were incubated with
primary antibodies directed against either p53 (Cell
Signaling), PCNA (Sigma), antiphosphorylated cdc-2
(Tyr15) (Cell Signaling) or anti-actin (Sigma), followed
by incubation with horseradish peroxidase-labelled sec-
ondary antibody. Chemiluminescence detection was then
carried out. Equal loading was confirmed by immuno-
staining for actin (Sigma).
Cell cycle analysis
Subsequent cell cycle analysis was determined using
propidium iodide DNA stain. After incubation with
fluorescein isothiocyanate-labelled cyclin B1, Ki-67 and
pan-keratin antibodies, cell cycle analysis was carried out
using propidium iodide (Sigma) and 100 mg/ml RNase
(Sigma) solution diluted in PBS. Fluorescence was
detected using a FACScan flow cytometer and analysed
using CellQuest software.
Assay for metabolic activity
Cell metabolic activity was measured using CellTitre 96
Aqueous One Solution Cell Proliferation Assay (Promega,
Southampton, UK). The kit was used according to the
manufacturer’s instructions and adapted for use in a 24-
well tissue-culture plate. Briefly, cells were seeded into
24-well plates and BrdU was added after 24 h. On day 7 of
treatment, the supernatant was removed and the 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulphophenyl)-2H-tetrazolium (MTS) salt reagent was
added to the cells in fresh culture media and incubated
for 1 h at 371C, in 5% CO2. Absorbance was measured at
450 nm using a Labsystems Multiscan microplate reader
(Labsystems, Helsinki, Finland).
Senescence assays
For lysosomal content and senescence-associated b-
galactosidase (SA-b-gal) activity, cells were seeded into
24-well plates and treated with BrdU as before.
Lysosomal content of the cells was determined using
the lysosomotrophic acridine orange stain (Sigma). Cells
were washed with PBS and incubated for 10min with
5 mg/ml acridine orange in PBS. After four washes with
PBS, cells were harvested by trypsinization and fluores-
cence was quantified by flow cytometry. SA-b-gal activity
was determined using the ImaGene Green C12FDG lacZ
detection kit (Molecular Probes) [39] according to the
manufacturer’s instructions. Briefly, cells were incubated
for 90min with 300 mmol/l chloroquine in culture
medium to inhibit endogenous b-galactosidase activity.
After washing with PBS, cells were incubated for 3 h with
33 mmol/l C12FDG, a fluorogenic substrate of b-galacto-
sidase. After two washes with PBS, cells were resus-
pended by trypsinization and fluorescence was quantified
immediately by flow cytometry as above. SA-b-gal was
also detected using an immunohistochemical X-gal stain
(Sigma). Briefly, cells were seeded in an eight-well
chamber slide and treated with BrdU as before. After 7
days, cells were fixed and stained using the kit according
to the manufacturer’s instructions.
Statistical analysis
All experiments were performed three times, unless
otherwise stated, and the results are presented as the
mean of these experiments with 95% confidence interval
of the mean. Wherever indicated, significance was
obtained using a two-sided Student’s t-test.
Results
5-Bromo-2-deoxyuridine activates DNA damage
response pathways in A549 cells
Both Chk1 and Chk2 proteins are transducers of DNA
damage responses and lie downstream of the ATM and
the ATR DNA damage sensors [40]. The ATR/Chk1
pathway has been implicated in responses to single-
strand breaks, whereas the ATM/Chk2 pathway is
involved in responses to double-strand breaks, although
there can be an overlap between the two pathways. Both
pathways are involved in mismatch-repair responses. p53
is activated in response to various cellular stresses by
phosphorylation at specific sites, depending on the
upstream signal [41]. We began by examining the DNA
damage response induced in BrdU-treated A549 cells.
Phospho-Chk1 and phospho-p53 (Ser 15) were detected
in control cells at culture day 7 (Figs 1 and 2a), indicating
background DNA damage response activity, which is
predictable in an aneuploid tumour cell line such as A549.
Cells cultured for 7 days in BrdU-containing medium
displayed increased DNA damage response activity, with
increased levels of phospho-Chk1 and the induction of
phospho-Chk2 (Fig. 1). Increased levels and nuclear
localization of total p53, increased levels of phospho-p53
(Ser 15) and induction of phospho-p53 (Ser 37, 46) were
also evident in response to BrdU treatment (Fig. 2a). An
increase in the levels of total p53 was confirmed by
Western blotting (Fig. 2b). Thus, several DNA damage
response pathways are activated in A549 cells in response
to BrdU exposure.
Altered morphology of 5-bromo-2-deoxyuridine-treated
cells
BrdU induced substantial changes in the morphology of
A549 cells. The incidence of binucleation, multinuclea-
tion, micronucleation and enlarged nuclei was increased
in A549 cells cultured with BrdU, compared with control
cells (Fig. 3a).
After 7 days of culturing, the BrdU-treated cells were
enlarged and flattened and resembled senescent-like
cells (Fig. 3a). Similar cells were present sporadically in
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control populations, but their incidence, estimated
microscopically to be approximately 1%, was significantly
lower than in treated populations. We were interested in
comparing enlarged BrdU-treated cells (BrdUL) with
large cells in control populations (CntlL) and with control
and treated cells that appeared to have more normal
morphologies (CntlN or BrdUN, respectively). We there-
fore defined the CntlL population as the largest 1% of the
total control population, according to their forward-
scatter properties by flow cytometry. We then used the
same gate to analyse the treated population (Fig. 3b).
Using this method, it was confirmed that the larger
morphology was approximately 10 times more prevalent
in treated populations (P<0.01). In addition, the
average size of the BrdUN cells was significantly greater
(P<0.001) than that of the CntlN cells, as indicated by a
shift in the forward scatter of the BrdU-treated popula-
tion (Fig. 3b and c).
Inhibition of cell proliferation by
5-bromo-2-deoxyuridine
BrdU significantly inhibited proliferation of A549 cells
(Fig. 3d). By day 7 of treatment, there was a 75%
reduction in cell number in BrdU-treated populations
compared with controls (P<0.05). This reduction in cell
number was not due to toxicity as the number of
nonviable cells remained low during culture in both
control and treated populations.
Modulation of cell cycle regulatory proteins in response
to 5-bromo-2-deoxyuridine
We proceeded to determine the effects of BrdU on cell
cycle regulatory proteins and to investigate the extent to
which cell cycle arrest, senescence and differentiation
were occurring in response to BrdU. PCNA plays an
essential role both in cell proliferation and in DNA repair
processes [42]. At day 1, BrdU-treated cells had increased
levels of nuclear PCNA, compared with control cells
(Fig. 4a). At day 7, however, BrdU-treated cells had
reduced levels of PCNA, compared with control popula-
tions, with some cells also exhibiting nuclear exclusion.
This might reflect initial attempts at PCNA-mediated
DNA repair, followed by downregulation of PCNA during
cell cycle inhibition. The reduction in PCNA expression
at day 7 was confirmed by Western blotting (Fig. 4b).
Cyclin D1, the G1 initiating protein, was virtually absent
in treated cells at day 7 (Fig. 5a). This, along with a
reduction in phosphorylated Rb protein (Fig. 5b),
indicates inhibition at the G1 and G1/S phase transition
point of the cell cycle [40].
The cyclin-dependent kinase inhibitors (CDKIs), p21,
p27 and p57, function primarily as negative regulators of
the cell cycle [43]. p21 plays a central role in cell cycle
regulation, apoptosis and differentiation [44], and has
inhibitory effects on cyclins at all phases. In control cells,
the number of p21-positive cells and the levels of p21
Fig. 1
Control +BrdU +BrdU DAPi
pChk1
pChk2
100 µm 100 µm 100 µm
100 µm 100 µm 100 µm
DNA damage-signalling responses in BrdU-treated cells. Phospho-Chk1 was detected in control cells (control) at day 7 of culture. Increased levels
of phospho-Chk1 and induction of phospho-Chk2 occurred in response to 7 days of BrdU treatment ( +BrdU). Nuclei were visualized using a DAPi
counterstain ( +BrdU DAPi). Abnormal nuclear morphology is indicated with an arrow. Results represent three experimental repeats. BrdU, 5-bromo-
2-deoxyuridine.
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protein per cell decreased during the culture period
(Fig. 6a). This very likely reflects an initial increase in
p21 activity to prevent the apoptosis following trypsiniza-
tion and a subsequent decrease on reattachment to
permit growth in culture. In contrast, p21 activity was
almost completely inhibited in BrdU-treated cells at day
1; thereafter, the levels increased and exceeded the levels
in the control cells by day 7 (Fig. 6a and b). Even at day 7,
Fig. 2
Control(a)
p53
p53ser15
p53ser37
p53ser46
Ctrl
53 kDa p53
Actin42 kDa
+BrdU
+BrdU
+BrdU DAPi
100 µm 100 µm 100 µm
100 µm 100 µm 100 µm
100 µm 100 µm 100 µm
100 µm 100 µm 100 µm
(b)
p53-signalling responses in BrdU-treated cells. (a) p53 and phospho-p53 (Ser 15) were detected in control cells (control) at day 7 of culture.
Increased levels of and nuclear localization of p53 and increased levels of phospho-p53 (Ser15, 37 and 46) occurred in response to 7 days of BrdU
treatment ( +BrdU). (b) Increased total p53 protein levels, as detected by Western blot. Nuclei were visualized using a DAPi counterstain ( +BrdU
DAPi). Binucleation is indicated with an arrow. Results represent three experimental repeats. BrdU, 5-bromo-2-deoxyuridine; Ctrl, control.
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Fig. 3
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Effects of BrdU on cell proliferation and morphology. (a) Actin immunofluorescence with DAPi counterstaining, which was visualized using confocal
microscopy, indicated increased cell size (dashed line arrow), binucleation (arrowhead) and micronucleation (arrow) in populations after 7 days of
BrdU treatment. (b) An overall increase in cell size was apparent in the BrdU-treated population by day 7, as indicated by a shift in forward scatter
(FSC) by flow cytometry. BrdUL cells were approximately 10 times more prevalent than CntlL cells. (c) The increase in cell size was significant in the
total populations and also when ‘normal’ sized (CntlN and BrdUN) and ‘large’ cells (CntlL and BrdUL) were compared, P<0.01 and P<0.001,
respectively. (d) BrdU induced a significant reduction of proliferation in A549 cells by day 7 of treatment (P<0.05). Results represent at least three
experimental repeats. BrdU, 5-bromo-2-deoxyuridine; Ctrl, control.
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p21 was present in only approximately 10% of the treated
cells (Fig. 6a). In contrast to p21, cells treated for 7 days
with BrdU also had increased levels of nuclear p27
(Fig. 6c) and p57 (Fig. 6d), compared with control cells.
5-Bromo-2-deoxyuridine activates cell cycle checkpoints
The effects of BrdU on cell cycle progression were
analysed. Ki-67 was used as a marker of actively cycling
cells to allow separation of 2C populations into G0 and G1
phases. When total populations were examined at day 7,
control cells displayed a normal cell cycle distribution.
They also displayed a larger 4C population, accounting for
approximately 8% of the total population, which pre-
sumably reflected the aneuploid nature of A549 cells
(Fig. 7a). In contrast, BrdU induced a significant increase
in the number of cells accumulated in G0 and S phase
with approximately 17 and 16% of the total BrdU
population in each respective phase, compared with 2
and 7% of total control populations. A corresponding
significant reduction in 2C/G1 phase BrdU-treated cells
was evident. This indicates that BrdU induced a
prolonged or halted S phase, which was probably due to
futile cycles of repair; it also caused cells to undergo
mitotic exit and to withdraw from the cell cycle into G0.
When BrdUN and BrdUL, as previously defined in Fig. 3,
were analysed separately, it was found that BrdUN cells
predominantly accounted for the halt at G0 (P<0.01)
(Fig. 7b). In contrast, approximately 40% of the BrdUL
cells were evenly divided between the S and the G2/M
phases; the latter distribution had not been apparent in
the analysis of the total population (Fig. 7c). Significantly
more BrdUL than CntlL cells were present in the
S (P<0.0001) and the G2/M phases (P<0.01). In
contrast, over 90% of CntlL cells were halted with a
greater 4C DNA content, significantly more than in
corresponding BrdUL cells (P<0.00001).
The cdc-2/cyclin B complex is pivotal in regulating the
G2/M checkpoint [40]. Phosphorylation of cdc-2 renders
it inactive. Downregulation of active cdc-2/cyclin B
Fig. 4
Control(a)
PCNA 
Day 1
PCNA 
Day 7
Ctrl
+BrdU
+BrdU
+BrdU DAPi
36 kDa PCNA
Actin42 kDa
(b)
100 µm 100 µm 100 µm
100 µm 100 µm 100 µm
Effects of BrdU on PCNA expression. (a) Nuclear PCNA was induced at day 1 of BrdU treatment. In contrast, PCNA was absent or at low levels in
control cells at this time point. Subsequently, PCNA levels increased in the control cells and decreased in the BrdU-treated cells after 7 days’
treatment with BrdU. Nuclear exclusion is indicated by an arrow. (b) Reduction in PCNA protein levels following 7 days of BrdU treatment, as
detected by Western blot. Results represent at least three experimental repeats. BrdU, 5-bromo-2-deoxyuridine; Ctrl, control; PCNA, proliferating
cell nuclear antigen.
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complexes is required for cytokinesis. Delayed degrada-
tion of cyclin B can lead to cytokinesis failure and mitotic
catastrophe with multinucleation and multimicronuclea-
tion, and can halt it at the G2/M checkpoint [45,46].
Although the percentage of control and treated cells
expressing cyclin B was similar during all the phases of
the cell cycle (data not shown), the amount of cyclin B
per cell was higher in treated cells, compared with
control, by day 7 (Fig. 8a). Increased cyclin B expression
was also associated with abnormal mitosis, both as
multinucleation and enlarged nuclei, in treated cells
(Fig. 8b). A slight increase in the activity of cdc-2 was also
suggested by a moderate decrease in its phosphorylation
levels (Fig. 8b and c). This suggests that cyclin B activity
is elevated in response to BrdU-mediated DNA damage,
leading to cell cycle arrest at the G2/M checkpoint.
Although this would lead to cell death in normal cells, the
dysregulated cell cycle machinery in A549 cells can result
in the G2/M halt and the mitotic catastrophe observed in
a subpopulation of these cells.
Induction of senescence-related markers in
5-bromo-2-deoxyuridine-treated cells
A range of senescence-related markers was used to
evaluate the induction of a senescence-like phenotype
in A549 cells in response to BrdU.
As shown above, increased numbers of large cells with a
senescent-like morphology were present in BrdU-treated
A549 populations (Fig. 3b and c). Moreover, there was
also an increase in average cell size in the BrdUN
population, compared with CntlN cells (Fig. 3c). When
cell size was compared with cell cycle phase in total
populations, it was found that BrdU-treated cells were
larger than control cells at all stages of the cell cycle.
Therefore, despite their increased size, BrdU-treated
cells remained capable of progressing through the cell
cycle and did not accumulate in any particular phase
(Fig. 9a).
Analysis of side scatter revealed a significant increase in
cell granularity in response to BrdU (P<0.01), which
again was evident at all cell cycle phases (Fig. 9b).
Granularity is considered to reflect an increased organel-
lar content in senescent cells [39]. Increased lysosomal
content is also associated with cellular senescence [39].
Lysosomal content was slightly increased in BrdU-treated
cells, compared with control cells, at day 7 as determined
by uptake of the lysosomotrophic fluorescent dye,
acridine orange (Fig. 9c). Separation of CntlN and BrdUN
populations from the CntlL and BrdUL populations
predictably showed that increased lysosomal content
correlated with increased cell size in both control and
treated cells.
BrdU-treated cells had a higher rate of metabolic activity
per cell than control cells (P<0.01) (Fig. 9d). This is
consistent with a senescence-like phenotype.
SA-b-gal activity was measured using two different assays.
Cleavage of the b-galactosidase substrate C12FDG,
measured by flow cytometry, revealed a significant
increase in SA-b-gal activity in BrdU-treated cells
Fig. 5
Control
Cyclin D1
pRb
(a)
(b)
+BrdU +BrdU DAPi
100 µm 100 µm 100 µm
100 µm 100 µm 100 µm
Effects of BrdU on cell cycle activators. (a) Cyclin D1 and (b) phospho-Rb expression was reduced in BrdU-treated cells by day 7 compared with
control cells. Results represent at least three experimental repeats. BrdU, 5-bromo-2-deoxyuridine.
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(P<0.01) (Fig. 10a). Staining of cells for SA-b-gal using
an X-gal substrate confirmed the increase in SA-b-gal
activity in response to BrdU (Fig. 10b).
Thus, per cell, BrdU-treated cells were larger, more
granular, had increased lysosomal content, were more
metabolically active and displayed more SA-b-gal activity
than their control counterparts; all these features indicate
the induction of a senescence-like phenotype.
Effects of 5-bromo-2-deoxyuridine on cell
differentiation
It has previously been reported that BrdU modulates the
expression of differentiation-related proteins such as
cytokeratins, which can be induced or upregulated in
lung cancer cell lines, depending on the endogenous
expression levels [23]. We investigated whether BrdU-
mediated upregulation of cytokeratin expression in A549
cells was cell cycle dependent. If so, this might reflect a
Fig. 6
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Effects of BrdU on p21, p27 and p57. (a) The number of control cells expressing p21 declined from approximately 20 to 7% during the culture
period. In contrast, p21 expression was inhibited by BrdU on days 1 and 3 of the culture. Although levels rose thereafter, no more than 10% of the
treated cells expressed p21. Results represent two experimental repeats. (b) p21 was weakly detectable by immunofluorescence in control cells at
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differentiation-related halt in the cell cycle. One hundred
percent of the control and the BrdU-treated cells
expressed cytokeratins (results not shown). Cytokeratin
expression, however, was significantly upregulated in all
treated cells during all the phases of the cell cycle
(P<0.01), with no accumulation occurring in any one
phase (Fig. 11).
Discussion
The ability of BrdU to both induce DNA damage and
modulate the cell phenotype has long been recognized.
The molecular mechanisms associated with these effects,
however, are unknown and potential links between the
two processes have not been explored. Furthermore, the
question of whether BrdU induces differentiation or
senescence requires clarification. We have examined the
effects of BrdU on DNA damage response and cell cycle
checkpoint pathways, and the related impacts on cell
cycle progression and cell phenotype in a lung cancer cell
line. BrdU-induced DNA damage occurs during several
cell cycle phases. The ‘multihit’ nature of BrdU-induced
DNA damage led us to examine unsynchronized cell
populations, thus enabling us to examine the ensemble of
BrdU effects. Our studies show that A549 cells respond to
BrdU-induced DNA damage by upregulating background
Chk1 responses, activating Chk2 and phosphorylating
p53. Activation of the DNA-repair function of PCNA is
also suggested by the early upregulation of this protein
after exposure to BrdU. A decoupling of normal DNA
damage signalling and cell cycle checkpoint activation in
these transformed cells leads to a deregulated mitosis
with an increase in the incidence of abnormal nuclei and
accumulation of cells in G0, S and G2/M phases of the cell
cycle. An increase in average cell size occurs and
phenotypic changes consistent with senescence are
apparent (summarized in Fig. 12).
Our findings thus support the contention that BrdU
induces a senescence-like phenotype in cancer cells.
Senescence is a mechanism to suppress inappropriate
proliferation, e.g. that follows DNA damage; it is defined
as an irreversible halt in cell cycle when cells become
unresponsive to mitogenic or apoptotic signals [27].
Senescent cells are enlarged and have increased granu-
larity; nevertheless, they remain viable and metabolically
active [47]. In this study, the A549 populations that
appeared morphologically normal were termed CntlN and
BrdUN. The majority of both of these populations had a
2C DNA content. Unlike the CntlN population, however,
approximately one-third of the BrdUN population had
withdrawn from the cell cycle and was halted at G0
(Fig. 7b). The BrdUN cells were also slightly larger than
their CntlN counterparts (Fig. 3d) and senescent-
associated features were increased in the BrdU-treated
2C population (Fig. 9). Despite their more ‘normal’
Fig. 7
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morphological appearance, therefore, the BrdUN popula-
tion had several senescent-like characteristics. It seems
likely that BrdU-induced DNA damage caused these cells
to arrest, in this case mainly at G0. The result of this
arrest was the induction of a senescence-like phenotype
rather than apoptosis.
Unlike the CntlN population, the enlarged CntlL
population, by definition, possessed senescent-like fea-
tures. The CntlL population, which represented only 1%
of the total control population, had increased cell sizes
and almost exclusively a greater 4C DNA content. These
cells probably reflected ongoing, spontaneous senescence
due to aneuploidy and in-vitro culture conditions in the
control population. In contrast, the incidence of enlarged
senescent-like cells was increased 10-fold in the presence
of BrdU. Unlike the CntlL population, approximately 50%
of BrdUL cells were accumulated in the S and G2/M
phases, indicating that they were halted at the DNA
damage checkpoints. Originally defined by their regula-
tory role in cell cycle progression, it is now clear that
DNA damage checkpoints are also involved in the
Fig. 8
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induction and maintenance of senescence [37,38,48]. We
therefore believe, first, that the previously reported
changes in gene expression and phenotype in BrdU-
treated tumour cells now seem to reflect the acquisition
of senescent-like phenotypes. Second, the activation of
the checkpoints in the A549 senescent-like cells in this
study provides evidence that these phenotypic changes
are due to BrdU-induced DNA damage responses, rather
than to mutations or to alterations in methylation or to
altered protein interactions in BrdU-containing DNA.
Although BrdU-induced morphological changes in A549
cells are consistent with the induction of a senescence-
like phenotype, the typical gene-expression profile for
senescence is not evident. Senescent normal human
fibroblasts typically overexpress p21, p16 and cyclin D1.
This was not the case in the present study [49].
Treatment-induced senescence of tumour cells can,
however, occur in the absence of p53, p21 and p16
[38,50]. The mechanisms underlying senescence in both
normal and tumour cells thus remain unclear. p21 is a
common mediator of p53-induced cell cycle arrest [43].
Downregulation of p21, however, occurred as an early
response to BrdU treatment, probably to avoid the
inactivation of the DNA repair function of PCNA [51],
indicating that the subsequent G0, S and G2/M check-
points activated by BrdU might be p21-independent.
Downregulation of p21 and the absence of p16 in A549
cells suggest that cell cycle arrest is mediated by p27
and/or p57, both of which are upregulated during BrdU
treatment.
The mechanisms by which cell cycle arrest is linked to
senescence are also unknown; although, p27 might play a
key role in linking the two processes. p27 induces cell
cycle arrest during several cell cycle phases usually in
response to external signals such as transforming growth
factor-b and contact inhibition [44]. Its expression,
therefore, correlates with differentiation status in normal
and cancer cells [52]. p57 is also involved in differentia-
tion and plays a role in alveolar development [53]. Both
p27 and p57 are also involved in senescence [54]. The
overexpression of p27 can lead to an increase in cell size,
protein content and metabolic activity, similar to the
BrdU-mediated effects seen in this study [55,56].
Upregulation of p27 to p57 may explain the appearance
of a senescence-like phenotype in BrdU-treated A549
cells in the absence of p21 and p16, which are usually
associated with senescence induction and maintenance
[47]. p27 and/or p57 could be responsible for most of the
cell cycle and phenotypic changes that occur in the A549
cells following BrdU-induced damage. The mitotic exit
and accumulation of G0 A549 cells following treatment
could be due to a p27/p57-induced differentiation-related
or senescence-related entry directly into G0, or to a p27/
p57-induced prolonged G1 halt, which leads to entry into
G0, or both. Increased cytokeratin protein could result
from an altered differentiation programme, terminal
differentiation, a senescence-related programme or
merely from an increase in cell size and accompanying
protein expression: all these can result from increased
p27/p57 activity.
It seems most likely that the altered phenotypes present
in BrdU-treated populations arise after sublethal DNA
damage responses. These responses, rather than leading
to apoptosis result in BrdU-specific cell cycle perturba-
tions, and the activation of regulators involved in cell
Fig. 10
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cycle arrest, differentiation and senescence. A precise
definition of these phenotypes as being either differ-
entiated or senescent might not be possible. Instead, we
suggest that these cells have a BrdU DNA damage-
induced altered phenotype that is dependent on their
genotype. Rather than a BrdU-specific effect such as
altered transcription factor binding to BrdU-substituted
DNA, p27-mediated/p57-mediated DNA damage re-
sponses (which involve mitotic exit and other cell cycle
halts) might, therefore, cause the phenotypic changes
observed in BrdU-treated A549 cells. It is possible that
the phenotypic changes observed in the other cell types
could also be explained by any, or a combination, of these
p27-mediated/p57-mediated processes.
The mechanisms by which BrdU induces various types of
DNA damage have been studied sporadically since this
thymidine analogue had first been designed as an
anticancer agent. Similarly, the effects of BrdU on cell
morphology and phenotype have been recognized but
unexplained for decades. These two aspects of BrdU
biology have remained relatively separate till date. We
suggest that there is very likely a connection between the
two. We provide evidence here that BrdU-mediated
effects on cell phenotype might be due, at least in part, to
BrdU-induced DNA damage and to the subsequent
perturbation of the cell cycle. As a result, phenotypic
response will vary between cell types, depending on their
respective DNA damage response and cell cycle machin-
ery. DNA damage-induced cell cycle perturbations can
lead to changes in gene expression that might resemble
differentiation or senescence. The latter remains poorly
understood, particularly in tumour cells [50]. Thus,
apparent cell-specific BrdU responses, particularly in
tumour cells that have abnormal and varying genotypes,
might reflect cell-specific DNA damage responses, rather
than BrdU-specific effects per se, such as altered
transcription factor binding to BrdU-containing DNA.
The ability of BrdU to modulate the cell cycle has
implications for its use in cell-proliferation assays in vitro
and in vivo. It also remains to be demonstrated whether
BrdU induces senescence in vivo when used during
chemotherapy. If so, is senescence beneficial or detri-
mental in this situation? Furthermore, other base
analogues that are used more commonly than BrdU for
cancer treatment might also have similar effects.
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